Trevena Stock Forecast, Price & News

2 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Trevena in the last year. There are currently 1 hold rating and 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" Trevena stock.
View analyst ratings for Trevena or view top-rated stocks.

2 equities research analysts have issued 1-year price targets for Trevena's stock. Their TRVN stock forecasts range from $3.50 to $6.00. On average, they expect Trevena's share price to reach $4.75 in the next year. This suggests a possible upside of 1,036.4% from the stock's current price.
View analysts' price targets for Trevena or view top-rated stocks among Wall Street analysts.

Trevena's stock was trading at $0.5830 at the beginning of 2022. Since then, TRVN shares have decreased by 28.3% and is now trading at $0.4180.
View the best growth stocks for 2022 here.

Trevena is scheduled to release its next quarterly earnings announcement on Thursday, August 11th 2022.
View our earnings forecast for Trevena.

Trevena, Inc. (NASDAQ:TRVN) posted its earnings results on Wednesday, May, 11th. The biopharmaceutical company reported ($0.10) earnings per share for the quarter, missing analysts' consensus estimates of ($0.09) by $0.01. The biopharmaceutical company had revenue of $0.02 million for the quarter, compared to analyst estimates of $0.65 million. Trevena had a negative net margin of 7,771.74% and a negative trailing twelve-month return on equity of 82.39%. During the same period last year, the business posted ($0.06) EPS.
View Trevena's earnings history.

Some companies that are related to Trevena include Provention Bio (PRVB), LianBio (LIAN), Verona Pharma (VRNA), AC Immune (ACIU), Inventiva (IVA), Alpine Immune Sciences (ALPN), Prelude Therapeutics (PRLD), InterCure (INCR), Rallybio (RLYB), Aadi Bioscience (AADI), KalVista Pharmaceuticals (KALV), Zomedica (ZOM), Sernova (SEOVF), Clovis Oncology (CLVS) and CymaBay Therapeutics (CBAY).
View all of TRVN's competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Trevena investors own include Conatus Pharmaceuticals (CNAT), Novavax (NVAX), Sorrento Therapeutics (SRNE), ADMA Biologics (ADMA), SCYNEXIS (SCYX), Matinas BioPharma (MTNB), Zosano Pharma (ZSAN), Aeterna Zentaris (AEZS), Bionano Genomics (BNGO) and Dynavax Technologies (DVAX).

Trevena trades on the NASDAQ under the ticker symbol "TRVN."

Trevena's stock is owned by many different retail and institutional investors. Top institutional investors include BlackRock Inc. (6.58%), Vanguard Group Inc. (4.28%), State Street Corp (1.66%), Northern Trust Corp (0.84%), GSA Capital Partners LLP (0.52%) and Renaissance Technologies LLC (0.19%).
View institutional ownership trends for Trevena.

TRVN stock was sold by a variety of institutional investors in the last quarter, including Vanguard Group Inc., Goldman Sachs Group Inc., Bank of America Corp DE, BlackRock Inc., Group One Trading L.P., Northern Trust Corp, and State Street Corp.
View insider buying and selling activity for Trevena or view top insider-selling stocks.

TRVN stock was purchased by a variety of institutional investors in the last quarter, including GSA Capital Partners LLP, Captrust Financial Advisors, Renaissance Technologies LLC, and Simplex Trading LLC.
View insider buying and selling activity for Trevena or or view top insider-buying stocks.

Shares of TRVN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of TRVN stock can currently be purchased for approximately $0.42.

Trevena (NASDAQ:TRVN) has a market capitalization of $69.19 million and generates $570 thousand in revenue each year. The biopharmaceutical company earns $-51.59 million in net income (profit) each year or ($0.35) on an earnings per share basis.

Trevena employs 25 workers across the globe.

Trevena's mailing address is 955 Chesterbrook Boulevard Suite 110, Chesterbrook PA, 19087. The official website for Trevena is www.trevena.com. The biopharmaceutical company can be reached via phone at (610) 354-8840 or via email at [email protected].